b'uFromPage 21MRD negativity at any time point (81.8%), withunprecedentedoutcomesfortransplant-eligible MRD negativity sustained for more than a year in(TE) and transplant-noneligible (TNE) patients. 62.6% of patients. With a median follow-up of 44However,outcomesremaindismalforpatients (TE) and 33 (TNE) months, median PFS was notwithMMwhohavehigh-riskdisease. Aswas reached in either arm, the authors added. recentlyreported,patientswithhigherSecond The researchers concluded that Isa-KRd effec- RevisionoftheInternationalStagingSystem tivelyinduceshighratesofsustainableMRD(R2-ISS) stages III and IV show a median pro-negativityinthedifficult-to-treatHRNDMMgression-free survival (PFS) of only 30 and 20 population, regardless of transplant status, trans- months, respectively.lating into a median PFS that was not yet reached1Chen Q, Zhang M, Zheng S, Tong Y, Tan Y. Therapeutic progress after 44/33 months. in relapsed/refractory multiple myeloma. Ann Hematol. 2024 NotingthatclinicaloutcomesinmultipleApr 13. doi: 10.1007/s00277-024-05730-y. Epub ahead of print. myeloma (MM) have greatly improved over thePMID: 38609727. pastdecadewiththeimplementationofnovel2Leypoldt LB, Tichy D, Besemer B, Hnel M, et. Al. Isatuximab, agents and continuous treatment approaches, theCarfilzomib, Lenalidomide, and Dexamethasone for the Treat-ment of High-Risk Newly Diagnosed Multiple Myeloma. J Clin authors suggested, Adding anti-CD38 monoclo- Oncol. 2024 Jan 1;42(1):26-37. doi: 10.1200/JCO.23.01696. nalantibodiestobackboneregimenshasledtoEpub 2023 Sep 27. PMID: 37753960; PMCID: PMC10730063.Multiple myeloma cells (MM) in blood flowsection view 3-D illustrationSource:Nemes Laszlo/Shutterstock22'